Dyne Therapeutics to Host Upcoming Investor Conference
WALTHAM, Mass. — Dyne Therapeutics, Inc. (NASDAQ: DYN), a company dedicated to advancing treatments for genetically driven neuromuscular diseases, is gearing up for a notable event. On December 8, the firm will share topline results from the Registrational Expansion Cohort of the Phase 1/2 DELIVER clinical trial, focusing on its innovative therapy, zeleciment rostudirsen (also known as DYNE-251), aimed at combating Duchenne muscular dystrophy (DMD).
Details of the Conference Call and Webcast
This significant conference will commence at 8:00 a.m. ET, coinciding with the announcement of the clinical trial results. Interested parties can access the webcast on Dyne's website, specifically on the Events & Presentations page found under the Investors & Media section. For those unable to attend live, a replay will be made available for 90 days following the presentation.
Background on the DELIVER Clinical Trial
The DELIVER clinical trial represents an essential step in Dyne’s research efforts. Zeleciment rostudirsen has shown promising potential in enhancing the quality of life for individuals diagnosed with DMD, a serious genetic disorder that primarily affects boys. The results from this trial are highly anticipated by investors and the medical community alike, as they could pave the way for significant advancements in treatment options.
About Dyne Therapeutics
Dyne Therapeutics is at the forefront of developing targeted therapies aimed at delivering meaningful improvements for individuals suffering from genetically driven neuromuscular disorders. The company actively advances its clinical pipeline, focusing on conditions such as myotonic dystrophy type 1 and Duchenne muscular dystrophy, while also exploring preclinical programs for other muscular dystrophies like facioscapulohumeral muscular dystrophy and Pompe disease.
Engagement and Social Media Presence
Dyne Therapeutics is not only dedicated to advancing science but also to engaging with the public and stakeholders. The company provides regular updates and shares insights into its research progress through its website and its various social media channels, including X, LinkedIn, and Facebook.
Customer and Investor Support Contacts
Dyne Therapeutics values its communication with investors. For inquiries, stakeholders can reach out to:
Investors
Mia Tobias
Email: ir@dyne-tx.com
Phone: 781-317-0353
Media
Stacy Nartker
Email: snartker@dyne-tx.com
Phone: 781-317-1938
Frequently Asked Questions
What is the purpose of the upcoming investor conference call?
The conference call will announce the topline results from the DELIVER clinical trial for zeleciment rostudirsen.
How can I access the webcast?
The webcast can be accessed through the Events & Presentations section on Dyne's official website.
What is zeleciment rostudirsen?
Zeleciment rostudirsen, also known as DYNE-251, is a therapeutic under investigation for its efficacy in treating Duchenne muscular dystrophy.
What is the importance of the DELIVER trial results?
The results from the DELIVER trial could significantly influence the future of treatment options for patients with Duchenne muscular dystrophy.
Who should I contact for investor inquiries?
For questions related to investments, please contact Mia Tobias at Dyne Therapeutics via email or phone.
